# Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance

> **NCT01191099** · — · UNKNOWN · sponsor: **University of Zurich** · enrollment: 150 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DEVICE:** Pimonidazol

## Key facts

- **NCT ID:** NCT01191099
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-08
- **Primary completion:** 2012-08
- **Final completion:** 2020-08
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01191099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01191099, "Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01191099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*